1258328-18-5Relevant articles and documents
Synthesis of novel substituted pyrimidine derivatives bearing a sulfamide group and their in vitro cancer growth inhibition activity
Lefebvre, Carole-Anne,Forcellini, Elsa,Boutin, Sophie,C?té, Marie-France,C.-Gaudreault, René,Mathieu, Patrick,Lagüe, Patrick,Paquin, Jean-Fran?ois
, p. 299 - 302 (2016/12/27)
The synthesis of two series of novel substituted pyrimidine derivatives bearing a sulfamide group have been described and their in vitro cancer growth inhibition activities have been evaluated against three human tumour cell lines (HT-29, M21, and MCF7). In general, growth inhibition activity has been enhanced by the introduction of a bulky substituent on the aromatic ring with the best compound having GI50??6?μM for all the human tumour cell lines. The MCF7 selective compounds were evaluated on four additional human invasive breast ductal carcinoma cell lines (MDA-MB-231, MDA-MB-468, SKBR3, and T47D) and were selective against T47D cell line in all cases except one, suggesting a potential antiestrogen activity.
Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: Alleviating hERG interactions through structure based design
Patel, Snahel D.,Habeski, Wendy M.,Cheng, Alan C.,de la Cruz, Elisa,Loh, Christine,Kablaoui, Natasha M.
scheme or table, p. 3339 - 3343 (2010/04/05)
PC-1 (NPP-1) inhibitors may be useful as therapeutics for the treatment of CDDP (calcium pyrophosphate dehydrate) deposition disease and osteoarthritis. We have identified a series of potent quinazolin-4-piperidin-4-ethyl sulfamide PC-1 inhibitors. The se
